KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $102.0 billion.

  • Pfizer's Total Non-Current Liabilities fell 836.92% to $102.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $102.0 billion, marking a year-over-year decrease of 836.92%. This contributed to the annual value of $6.2 billion for FY2024, which is 345.12% up from last year.
  • As of Q3 2025, Pfizer's Total Non-Current Liabilities stood at $102.0 billion, which was down 836.92% from $103.2 billion recorded in Q2 2025.
  • Pfizer's Total Non-Current Liabilities' 5-year high stood at $113.4 billion during Q1 2024, with a 5-year trough of $5.2 billion in Q4 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $89.6 billion (2022), whereas its average is $70.4 billion.
  • As far as peak fluctuations go, Pfizer's Total Non-Current Liabilities tumbled by 1330.3% in 2021, and later skyrocketed by 50148.08% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Total Non-Current Liabilities stood at $6.5 billion in 2021, then dropped by 8.26% to $6.0 billion in 2022, then rose by 0.03% to $6.0 billion in 2023, then grew by 3.45% to $6.2 billion in 2024, then skyrocketed by 1544.32% to $102.0 billion in 2025.
  • Its Total Non-Current Liabilities was $102.0 billion in Q3 2025, compared to $103.2 billion in Q2 2025 and $104.1 billion in Q1 2025.